---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-036357"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-21T00:08:45.826308+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# INBS closes $220k private placement of Series D convertible preferred and warrants

## Summary
- Gross proceeds of $220,585 from sale of 176,462 Series D convertible preferred shares and 529,386 warrants at $1.25/unit.
- Each preferred share initially convertible into 3 common shares; warrants exercisable at $0.29/share for 5 years.
- Conversion requires shareholder approval; preferred shares carry voting rights only on reverse stock split proposals.
- Insider participation: CFO Spiro Sakiris ($19,991) and Director Manuel Kostandas ($13,327) purchased 26,655 units combined.
- Proceeds to be used for general working capital; placement agent Winx Capital receives 6% fee and 26,469 warrants.

## SEC filing metadata
- accession: 0001493152-22-036357
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315222036357/0001493152-22-036357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315222036357/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-036357
- JSON: https://secwatch.observer/filing/0001493152-22-036357.json
- Plain text: https://secwatch.observer/filing/0001493152-22-036357.txt

## Key facts
- Material Agreements
  INTELLIGENT BIO SOLUTIONS INC. entered into Purchase Agreement with 14 investors valued at $220,585 (effective 2022-12-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: 14 investors
  - Value: $220,585
  - Effective: 2022-12-21
  source text: On December 21, 2022, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with 14 investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a Regulation S private placement (the “Transaction”) (i) 176,462 shares of the Company’s Series D Convertible Preferred Stock (the “Preferred Stock”), par value $0.01 per share (the “Preferred Stock”), and (ii) 529,386 warrants (the “Warrants”), with each Warrant representing the right to purchase one share of the Company’s common stock (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315222036357/0001493152-22-036357-index.htm
- Material Agreements
  INTELLIGENT BIO SOLUTIONS INC. entered into Engagement Letter with Winx Capital Pty Ltd. (effective 2022-12-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Winx Capital Pty Ltd.
  - Effective: 2022-12-16
  source text: On December 16, 2022, the Company entered into Engagement Letter (the “Engagement Letter”) with Winx Capital Pty Ltd. ( CAR for AFSL (Australian Financial Services License) #330757) (“Winx Capital”) pursuant to which Winx Capital agreed to serve as a consultant acting as placement agent on a best efforts basis in connection with the private placement of the Units in the Transaction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315222036357/0001493152-22-036357-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.